Compared with the control group, TFOs (HER2-205) treatment of HER2-positive breast cancer xenografts resulted in a 52% reduction in tumor volume, equivalent to the 58% reduction observed with trastuzumab. Here, ERBB2 is linked to breast carcinoma.